EC-5026 in Chronic Kidney Diseases: NCT07694544 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
18
Planned enrollment
2026-12-31
Primary-completion proxy
Executive view
NCT07694544 evaluates EC-5026 in Chronic Kidney Diseases. The disclosed sponsor is Eicosis Human Health, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t), assessed over 14 days.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07694544 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Chronic Kidney Diseases landscape. Drug & Asset MCP drug_fetch was queried for EC-5026, while Company & Deal Intelligence MCP organization_fetch was queried for Eicosis Human Health, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07694544 | EC-5026 | Phase 1 / Recruiting | Eicosis Human Health, Inc. | United States | Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) 14 days | 2026-12-31 |
| PACTR202607678798356 | Febuxostat | Not Applicable / Complete | Sponsor not reported | Egypt | Timing not reported | |
| TCTR20260721005 | Ferrous Sulfate/Ascorbic Acid | Phase 3 / Recruiting | Navamindradhiraj University | Thailand | 2027-04-30 | |
| ISRCTN16119881 | Erythropoietin(Xiamen Amoytop Biotech Co. Ltd.) | Not Applicable / No longer recruiting | Sponsor not reported | China | 2024-06-30 | |
| NCT07704190 | Secukinumab | Phase 4 / Not yet recruiting | Peking University Third Hospital | Geography not reported | Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardi… From randomization up to 2 years | 2028-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07694544 is a Phase 1, recruiting study with 18 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)” over “14 days.” The retrieved endpoint description is: The area under the plasma concentration-time curve from dosing until the last measurable concentration. Plasma concentrations will be measured from blood samples collected at prespecified time points (0, 2, 4, 6, 8, 24 hours, and 3, 5, 7, 14 days after administration) using a validated bioanalytical assay. AUC0-t will be calculated using noncompartmental pharmacokinetic methods and represents systemic exposure to the study drug over the measured sampling interval..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Chronic Kidney Diseases. These records do not establish direct evidence for NCT07694544 unless the registration number matches.
Hydroxychloroquine for the Management of CVD in CKD
Phase 2; n=100; Baseline(Mean) = 1674.38 mm3 (Standard Deviation, 439.89); Baseline(Mean) = 1498.57 mm3 (Standard Deviation, 341.54) Source: https://clinicaltrials.gov/ct2/show/results/NCT03636152
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C…
Phase 2; n=143; Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median) = -14.8 Time-Averaged Percent Change in hsCRP (Inter-Quartile Range, -35.8 to 17.4); Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median): Median Difference (Net) = -59.817(95% CI, -79.690 to -39.943), P-Value = <0.0001; Median Difference (Net)… Source: https://clinicaltrials.gov/ct2/show/results/NCT06362759
Finerenone in Persons with Chronic Kidney Disease without Diabetes
Phase 3; n=1584; eGFR(mean annual rate of change) = -4.0 ml/min/1.73 m2 ( -4.3 to -3.8); eGFR(mean annual rate of change) = -3.3 ml/min/1.73 m2 ( -3.6 to -3.1) Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42246672/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
EC-5026 is indexed as Small molecule drug with EPHX2 biology and a global stage of Phase 1/2. The asset profile lists Eicosis Human Health, Inc. as an originator or developer.
Eicosis Human Health, Inc. is indexed in United States with the website http://www.eicosis.com. EicOsis Human Health is developing a first-in-class therapy of a once daily The record lists 6 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether EC-5026 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07694544
Protocol source: https://clinicaltrials.gov/study/NCT07694544
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
EC-5026 in Chronic Kidney Diseases is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) and 2026-12-31 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
